COMMUNIQUÉS West-GlobeNewswire

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
08/09/2026
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the [...]
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
08/09/2026
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart [...]
Acquisition of Own Shares
08/09/2026
Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
08/09/2026
Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare [...]
Celldex to Present at Upcoming Investor Conference
08/09/2026
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8: [...]
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
08/09/2026
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
08/09/2026
Event to be webcast live on September 9, 2026 at 7:30 a.m. ET BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for [...]
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
08/09/2026
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare [...]
Inventiva to Present Multiple Abstracts at Paris MASH 2026
08/09/2026
Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes Preclinical data further characterize lanifibranor’s [...]
Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026
08/09/2026
Des données d’études cliniques de Phase 1 et Phase 2 montrent que le lanifibranor améliore le profil métabolique et certains facteurs de risque cardiovasculaire chez les patients atteints de MASH, avec ou sans diabète [...]
Starton Therapeutics Appoints Experienced Finance Executive Saleem Elmasri, CPA, as Chief Financial Officer
08/09/2026
Experienced finance executive and former Big Four auditor to lead corporate finance strategy, and capital markets initiatives PARAMUS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc . (“Starton”), a [...]
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
08/09/2026
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million [...]
XORTX Re-Engages Investor Relations Program
09/09/2026
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture [...]
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the [...]
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
08/09/2026
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in [...]
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
08/09/2026
TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q [...]
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
08/09/2026
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo ® (berotralstat), a plasma kallikrein [...]
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
08/09/2026
U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28,   2027 If approved, Oxnimbi has the potential to [...]
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
08/09/2026
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H. [...]

Pages